Mirum says LIVMARLI met primary endpoint in Phase 3 EXPAND study
Mirum Pharmaceuticals announced that LIVMARLI (maralixibat) met the primary endpoint in the Phase 3 EXPAND study of ultra-rare cholestatic liver diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mirum Says LIVMARLI Phase 3 EXPAND Study Met Primary Endpoint
Mirum Pharmaceuticals announced topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) in patients with ultra-rare cholestatic liver diseases, reporting that the primary endpoint was met.